Compare MasterCard Inc (MA) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs ResMed Inc. — how do they compare? MasterCard Inc trades at $574.4 (market cap $503.50B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: MasterCard Inc is far larger — about 15.8× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 134 Days and ResMed Inc. for 51 Days on average.
| MA | RMD | |
|---|---|---|
Market Cap | $503.50B | $31.89B |
Volume | 3,390,859 | 618,314 |
Sector | Financials | Health |
52-Week High | $599.86 | $277.88 |
52-Week Low | $471.55 | $182.82 |
Typical Hold Time | 134 Days | 51 Days |
Enterprise Value | $516.53B | $31.24B |
Dividend Yield | 0.61% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $570.06, up 0.61% with a bullish technical signal and strong institutional interest. The company demonstrates robust fundamentals with 2025 revenue of $32.79B and net income of $14.97B, maintaining exceptional profitability margins. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $5.04 surpassing the $4.77 estimate. Analyst consensus remains strongly positive with 80% buy ratings and a $666.67 price target, representing 17% upside potential from current levels.
Mastercard presents a compelling growth opportunity with expanding digital payments adoption and strong execution, though faces risks from payment industry disruption and competitive threats. The stock's premium valuation (P/E 31.36) reflects high growth expectations that must be sustained. Near-term catalysts include Q3 2026 earnings and continued AI payment innovation, while regulatory scrutiny and economic sensitivity remain key monitoring points for investors.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
